ArQule, Daiichi Sankyo initiate enrollment in tivantinib Phase 3 trial for hepatocellular carcinoma Daiichi Sankyo Company, Small and ArQule, Inc. today announced that the first patient has been enrolled in the pivotal Phase 3 METIV-HCC trial of tivantinib cialis 20mg sverige read more . Tivantinib, an investigational selective inhibitor of MET, a receptor tyrosine kinase, has been evaluated for the treating patients identified as having hepatocellular carcinoma who’ve received one or two prior systemic anti-malignancy therapies. The METIV-HCC trial is normally a randomized, double-blinded, controlled study of previously treated patients with MET-high inoperable HCC who’ll receive placebo or tivantinib.

http://www.swecialis.com

Arcion receives U.S. Patent allowance for ARC-2022 to treat PHN Arcion Therapeutics, a clinical stage biotechnology business developing topical therapies for chronic pain, today announced that it received notice of allowance for a US Patent because of its high power gel formulation of topical lidocaine, ARC-2022. ‘With ARC-2022 our objective is to provide lidocaine to your skin without the necessity of an occlusive patch. Campbell, MD, CEO and President of Arcion. ‘We are on track to advance ARC-4558 for painful diabetic neuropathy into Phase 3 studies and ARC-2022 into further Phase 1/2 studies in 2012. ARC-4558 has received fast-track position with the FDA.’.